Auris Medical Provides Update on Bentrio Program in Allergy
07 mai 2021 09h05 HE
|
Auris Medical AG
BentrioTM meets primary efficacy endpoint in clinical evaluation in allergic rhinitisClinically relevant and significant reduction in nasal symptomsSuperior efficacy ratings by patients and clinicians...
Auris Medical Announces Positive Preclinical and Clinical Outcomes with AM-301 and Details Plans for Market Launch
13 avr. 2021 07h45 HE
|
Auris Medical AG
Clinical evaluation of AM-301 nasal spray in allergic rhinitis meets primary endpoint Extended protection achieved over several hoursPreliminary preclinical data suggest therapeutic utility post...
Auris Medical to Provide Business Update on AM-301 Program on Tuesday, April 13, 2021
08 avr. 2021 08h00 HE
|
Auris Medical AG
Hamilton, Bermuda, April 8, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
Auris Medical Provides Business Update and Reports Second Half and Full Year 2020 Financial Results
31 mars 2021 08h30 HE
|
Auris Medical AG
Clinical evaluation of AM-301 nasal spray in allergen protection progressingLaunch of AM-301 expected in selected markets towards the end of second quarter 2021 Phase 2 trial with AM-125 in acute...
Auris Medical to Report Second Half and Full Year 2020 Financial Results and Provide Business Update on Wednesday, March 31, 2021
24 mars 2021 08h00 HE
|
Auris Medical AG
Hamilton, Bermuda, March 24, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology,...
Auris Medical Announces Initiation of Clinical Investigation of AM-301 in Allergic Rhinitis
29 janv. 2021 08h30 HE
|
Auris Medical AG
Hamilton, Bermuda, January 29, 2021 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Provides Business Update
15 déc. 2020 08h30 HE
|
Auris Medical AG
Net cash inflow of $13.4 million from recent registered direct offering and warrant exercises AM-301 program progressing towards clinical and regulatory milestones Strategy review ongoing Hamilton,...
Auris Medical Holding to Present at the 13th Annual LD Micro Main Event Conference
07 déc. 2020 16h10 HE
|
Auris Medical AG
Hamilton, Bermuda, December 7, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...
Auris Medical Holding Ltd. Prices $8,000,000 Common Shares Offering Priced At-the-Market
02 déc. 2020 08h45 HE
|
Auris Medical AG
Hamilton, Bermuda, December 2, 2020 – Auris Medical Holding Ltd. (NASDAQ: EARS) (“Auris” or the “Company”), a clinical-stage company dedicated to developing therapeutics that address important unmet...
Auris Medical Reports Positive In vitro Efficacy Data for AM-301 in Protecting Against Sars-CoV-2 Infection
01 déc. 2020 09h00 HE
|
Auris Medical AG
Up to 99.4% reduction of viral titer in human epithelial cell culture (p<0.001)Results suggest potential for AM-301 nasal spray to mitigate risk of Sars-CoV-2 infection Hamilton, Bermuda, December...